Navigation Links
Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
Date:7/13/2008

NASHVILLE, Tenn., July 14 /PRNewswire/ -- A newly available treatment already has benefited several individuals with aggressive malignancies. Offered through NeoPlas Innovation, this regimen has arrested or eradicated tumors in more than 80% of initial patients. Director of Research Dr. Stephen Cantrell emphasized that human testing is in its early stages, but added, "These results have surprised us. This is far beyond what currently available standard treatments achieve."

Melanoma, a deadly form of malignant skin cancer, is among the diseases targeted to date. The first person treated with the investigative protocol had stage 4 melanoma and a life expectancy of eight weeks. He experienced a complete response and remains disease-free eight years later. While not all results have been this dramatic, each NeoPlas melanoma patient has had results significantly better than those with standard therapy. Eradication of tumors or long-term stability has occurred in most patients; others have seen a substantial slowing of progression.

The new protocol incorporates a unique combination of FDA-approved drugs used by millions of people for other applications. When administered alone, these drugs show some benefit against cancer, but not enough to make a difference for most patients. The combination of the medicines, however, allows lower, more tolerable dosages and provides effectiveness not seen in previous, single-drug studies.

The NeoPlas treatment disables certain abnormal cellular processes many of the aggressive malignancies share. Based on experience and relevant lab research to date, staff members expect the best results for: melanoma, pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma. The regimen is not expected to have significant benefit against brain tumors.

The most notable side effect is fatigue. Most patients never experience side effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors all treatment and maintains close communication with the patient's established oncologist. Having received previous cancer treatments does not make a patient ineligible for the outpatient NeoPlas regimen.

A Web site, http://www.neoplas.org, provides answers to common questions and an interactive screening tool. Individuals can reach NeoPlas at 615-371-8100 or by e-mailing office@neoplas.org.


'/>"/>
SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
2. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
3. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
4. Patients Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
5. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
6. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
7. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
8. Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
11. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
(Date:3/24/2017)... , March 23, 2017  HealthMine surveys with ... 2017 revealed that health plan members want help from ... to stay engaged in their health, 2) help closing ... integrated platform for health and 5) relevant, real-time guidance. ... and lowering healthcare costs. A ...
(Date:3/24/2017)... GENEVA , March 24, 2017 /PRNewswire/ ... Day revitalizes efforts to develop sutezolid as effective response ... Tuberculosis Day, TB Alliance and the Medicines Patent Pool ... of sutezolid, an antibiotic drug candidate which demonstrated encouraging ... development of sutezolid in combination with other TB drugs ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... “The Adventures of Joey, The Dog Who Barks at ... his life to the fullest, as God intended. “The Adventures of Joey, The Dog ... and grandmother pursuing her passion for writing, especially about truth and human behavior. , ...
(Date:3/23/2017)... ... , ... A recent report from the National Council on Teacher Quality (NCTQ) ... suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions in ... It argues that this higher bar should be set by states, by the Council ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... their communities, 16 more public health departments have been awarded national accreditation through ... 4.5 million people into the expanding network of communities across the nation whose ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Oklahoma City Convention Center at 10 North Broadway Avenue, will be an educational ... of relevant, practical instruction in the management of chronic pain. , Oklahoma is ...
(Date:3/23/2017)... ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of ... had a significant impact on the careers of all others involved. , On ... inducted into the MBI’s Hall of Fame. The induction took place during the World ...
Breaking Medicine News(10 mins):